HER-2 Gene Amplification clinical trials at UC Cancer

1 research study open to eligible people

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
open to eligible people ages 18 years and up
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
at UCLA

Last updated: February 17, 2023